Who needs and continues to need paediatric palliative care? An evaluation of utility and feasibility of the Paediatric Palliative Screening scale (PaPaS)

Poh Heng Chong 1* 1, Janice Soo 2, Zhi Zheng Yeo 1, Raymond Qishun Ang 1 and Celene Ting 1

Abstract

Background: While the populations of children who can benefit from paediatric palliative care (PPC) have been broadly defined, identifying individual patients to receive PPC has been problematic in practice. The Paediatric Palliative Screening scale (PaPaS) is a multi-dimensional tool that assesses palliative care needs in children and families to facilitate timely referrals. This study evaluates its use to manage new referrals and ongoing review of patients receiving home-based PPC in Singapore.

Methods: Using a retrospective cohort study design, 199 patients admitted to receive PPC via clinician screening were scored using PaPaS. Eighty-four patients in two groups were scored again at one of two following milestones: one-year service continuation mark or point of discharge before a year. Accuracy measures were compared against clinical assessment.

Results: 96.98% of patients scored 15 and above on admission (indicating need for PPC). Patients assessed at following milestones were effectively stratified; those who continued to receive service after 1 year scored significantly higher (M = 19.23) compared to those who were discharged within a year (M = 7.86). Sensitivity and specificity for PaPaS were calculated at 82.54 and 100% respectively. Overall congruence with clinician-based decisions supports the utility of PaPaS as a screening tool in PPC. Recommendations to improve the scale further are proposed.

Conclusion: The PaPaS is a practical screening tool that signposts PPC needs within the clinical setting. This facilitates early referrals to PPC, without having to specify individual prognoses that are often uncertain. Other benefits include optimised continuity of care and implications for resource allocation.

Keywords: Paediatric palliative care, Home hospice, Needs assessment, Screening tool, Admission

Background

As part of a growing movement to improve the care of seriously-ill children, Paediatric Palliative Care (PPC) services around the world face a myriad of challenges. Other than securing sustainable funding [1, 2], efforts to promote service access, both in the patient community and among healthcare providers, have been described [3–5]. In addition, at service transition after a referral to PPC has been made, good communication between healthcare professionals is critical [6], not only for access, but also continuity of care and patient safety [7].

While ethos and approaches are similar, the scope of work in adult and paediatric palliative care can differ [8]. In contrast to most life-threatening illness such as cancers in the adult-setting, both children with life-threatening and life-limiting illness (henceforth combined under ‘life-shortening illness’) present a wide variety of diagnoses. These are broadly categorised into four typologies that include congenital anomalies, metabolic diseases, neurological conditions and conditions
that are non-progressive, like cerebral palsy [9]. In fact, the cohort with oncological diagnoses number just around 20–30% [10, 11] in most PPC patient census. Average length of service in PPC is generally longer than that in adult palliative care [12]. Disease trajectories are often uncertain and can differ widely, even between children with the same diagnosis; individual survival can vary from hours to more than 20 years [13, 14]. Heterogeneity in qualifying medical conditions and overall longer survivals are hallmarks of PPC that together increase the complexity in service planning and implementation [15].

Given all the above considerations, eligibility for PPC is necessarily needs-based rather than prognosis-driven; and an objective tool that clearly defines the patient or family with PPC needs is indicated [16]. In addition to accounting for complex needs and longer length of service, such a tool can help address concerns about service sustainability by providing justification for allocating scarce resources between children with varying needs. Finally, a structured and standardised approach to case referrals can also improve communication between providers at point of referral or handover.

Internationally, the populations of children who can benefit from PPC have been defined [17, 18]. Yet, referrals are often made late or not at all [19]. Though the ‘surprise question’ used effectively in the adult setting has been found to be equally sensitive as a prognostic tool in children [20], it is still inadequate as a screening tool within the PPC ethos of holistic family-centred care that starts from diagnosis.

The Spectrum of Children’s Palliative Care Needs has been conceived to incorporate exactly these multi-dimensional elements, grouping children who are eligible for PPC into five prognostic-based categories with distinct care needs [21], though these needs have not been explicitly specified. This framework remains problematic, with participants in an early validation exercise commenting that categorisation still needed their own consolidated assessments that included: clinical symptoms, treatment outcomes, dependency indicators, psychosocial factors, and patient/carer priorities.

One promising tool for screening patients for PPC needs is the Paediatric Palliative Screening scale (PaPaS) [22]. The PaPaS targets timely referrals to PPC through identifying (screening for) children with palliative care needs. It consists of a series of questions in five domains, which are almost the same domains described in the Spectrum of Needs framework [21]. Each question is weighted and assigned a score depending on the response [23]. The total score is then used to stratify patients into different courses of action; a score of 15 and above indicates that PPC could be initiated [22, 23].

Other than the original authors who had conceived and validated the PaPaS, there have not been published reports of its application in other settings. Prior to its implementation in local policy and practice, we performed an evaluation of the utility and feasibility of the PaPaS as an admission-screening tool within a home-based PPC service. Besides admission, we also explored its use in relation to continuation of PPC, such as reassessment after one year. Our findings, experience and recommendations are reported in this paper.

The primary objective of this study is to assess the utility and feasibility of PaPaS as a referral screening tool to identify paediatric patients who may require PPC. The secondary objective evaluates the utility of PaPaS to determine continuation of PPC after one year.

Methods

Design

A non-interventional, retrospective cohort study design was adopted, using data collected as part of standard service provision. For the primary objective, action plans recommended by the PaPaS were compared against those by clinician assessment, the common standard to determine patient admissions. For the secondary objective, we hypothesise that PaPaS can distinguish between patients suitable for interim discharge and those who require continuation of PPC beyond the first year. To this end, two groups of patients—those who continued to receive PPC after one year and those discharged within a year—were assessed using the PaPaS a second time based on their respective end-points, and their scores compared.

Setting

The patient population studied received home-based PPC from a specialist paediatric palliative care service in Singapore. The service is nested within the nation’s largest home hospice service, which provides palliative and supportive care for patients at home. A team of eight multi-disciplinary healthcare providers is dedicated solely to the care of paediatric patients.

All patients admitted have life-shortening conditions as described by Association for Children’s Palliative Care and the Royal College of Paediatric and Child Health [9]. Like similar services elsewhere [6, 11], the team serves a majority of young persons with non-cancer diagnoses (80% of cases). New referrals come mainly from tertiary children hospitals that are government funded, with occasional referrals from private paediatricians or oncologists.

Pre-PaPaS, referrals were screened for admission based on the clinical judgement of a single physician trained in paediatric palliative medicine. As part of normal workflow, patients were also reviewed periodically afterwards at multi-disciplinary team (MDT) meetings, for service continuation or interim discharge.
Data collection

The study included patients admitted into the service between Apr 2012 and July 2016. No age limits were set. Data was extracted from electronic records in the team’s patient management system.

Scoring was determined by JS, who reviewed patient records at the appropriate time-points, and chose the responses that best fitted descriptions in the records. Information relevant to the PaPaS were never explicitly requested from referring sources before. Hence, a flexible approach to assigning scores was adopted; for each patient, JS studied multiple sources of information (e.g. referral forms, discharge summaries from referring institutions, and notes from internal medical records) to impute scores. The scores were corroborated by PHC, who scored a sub-sample of 20 randomly selected patients (10% of sample) to ensure agreement. Where information required for scoring items in the PaPaS was insufficient or missing, these patients were excluded from analysis. A referral form may have no mention of ‘symptom intensity’ or ‘difficulty of symptom control’, which prevents scoring of one item in the original scale [22]. This patient for example would be excluded from our analysis.

For the second assessment, two groups of patients were identified within the sample: patients who received PPC for more than 1 year, and patients who were discharged before 1 year. PaPaS scores were imputed a second time for individual patients using information either at the one-year mark or at point of discharge. Patients not belonging to either groups were excluded. Sensitivity and specificity values for the screening scale at these subsequent milestones were determined.

All scores were tabulated using Microsoft Excel 2016; statistical analyses (e.g. Student t-test and Chi-squared tests) and presentation of distributions (box-plots) were done with STATA 15. The STARD guidelines is referenced in structuring this report [24].

Results

Figure 1 details the flowchart for the study population. Two hundred twenty-eight patients were referred for PPC at home between April 2012 and July 2016. Twenty-nine patients (12.71%) were excluded due to insufficient or missing information; the First Assessment scored 199 patients (at point of referral). Eighty-four patients were included in the Second Assessment involving

![Fig. 1 Study population flowchart](image-url)
two groups; 115 patients were excluded for various reasons (listed in Fig. 1).

First assessment
Table 1 summarises the demographics of patients at First Assessment. Figure 2 shows the box-plot distribution of PaPaS scores for the First Assessment. Scores ranged from 10 to 32 points, with a mean score of 23.71 (SD: 4.43; Median score 25). One hundred ninety-three patients (96.98%) scored 15 and above.

Second assessment
For the Second Assessment, 84 patients in two groups were reassessed with PaPaS. Table 2 shows their demographics; there were no significant differences in age, gender, or diagnosis types between groups (p > .05).

Table 3 shows the distribution of patients between groups, based on their PaPaS scores. We hypothesised that patients who scored 0–14 on the PaPaS could be considered for discharge, while those who scored 15 and above eligible for continuation of PPC. For actual patients in the ‘continued service’ group, 52 scored above 15 points, whereas all discharged patients (n = 21) scored less than 15. Compared against standard clinical assessment for discharge and service continuation, the PaPaS demonstrated a sensitivity of 82.54% and a specificity of 100%. Patients who continued to receive PPC after one year had a significantly higher mean score compared to patients who were discharged within one year (p < .001).

Discussion
To our knowledge, this is the first utility and feasibility study on the PaPaS—to screen patients for specialist PPC and make decisions to retain/discharge existing patients. Findings demonstrate that recommended action plans according to PaPaS scores were largely congruent with decisions made through case assessment, whether by a single clinician or MDT. Although this study was not aimed at validation, real patients’ data were used to provide substantive support for the PaPaS’s utility in identifying paediatric patients with palliative care needs [17, 18]. By comparing imputed scores with actual events in practice (i.e. clinical decisions around acceptance of new referrals), some indication of criterion validity for the PaPaS is rendered.

The PaPaS demonstrates intrinsic benefits of transparency and reliability. An objective and standardised scoring system helps to overcome variation in referral patterns among paediatricians that stem from differential interpretations of what palliative care entails [25]. The checklist approach to screening for...
palliative care needs is also advocated by expert consensus in the adult setting [26]. Such a tool can potentially aid policy makers in evidence-based planning, resource allocation and cost-effective commissioning of new services [27]. However, some outliers may remain that still require case-by-case consideration using alternative approaches, such as individual assessments by a clinician who is familiar with the principles of PPC.

In some settings, practitioners may find PaPaS useful for the purpose of resource allocation; to identify patients who no longer require specialist PPC after a period of intensive case management [19]. With some modifications, PaPaS demonstrates potential not only as an assessment tool for planning intake, but also discharge from and continuation of PPC. Given uncertain trajectories and huge diversity in diagnoses over wide neurodevelopmental ages, some services can consider segmentation of patients and families for long-term service sustainability. The facility for temporary discharge from PPC while the child continues to consult primary physicians in tertiary institutions is one option. The PaPaS appears to support this exercise when indicated. In fact, since late 2017, the Ministry of Health in Singapore has adopted the PaPaS to determine eligibility for home-based PPC; it is administered both on admission, and assessment for service continuation at 1 year and every year thereafter.

Another key objective in this study is to explore feasibility aspects of the instrument. In the process of imputing scores for individual patients, several ways to improve its administration were identified. These observations and suggestions are summarised in Table 4 for users’ consideration. A proposed new version of the scale is designed (Appendix) based on these comments.

Implications
With finite public health funding for PPC programmes, the PaPaS emerges as a tool that can systematically identify patients and families who will benefit from resource-intensive PPC at the specialist level. Widespread adoption of PaPaS may improve understanding of what PPC involves, resulting in timely referrals from paediatricians who may otherwise be unfamiliar with PPC or its service eligibility.

### Table 2 Demographics of patients at Second Assessment (N = 84)

| Demographics | Discharged (n = 21) | Continued service (n = 63) |
|--------------|---------------------|---------------------------|
| **Age at referral** | | |
| Median age in years (IQR) | 15.8 (10.3) | 12.6 (11.4) |
| Minimum age in days | 81 | 119 |
| Maximum age in years | 30.2 | 34.1 |
| **Gender** | | |
| Female (%) | 8 (38.1%) | 32 (50.8%) |
| Male (%) | 13 (61.9%) | 31 (49.2%) |
| **Type of diagnosis** | | |
| Cancer (%) | 0 | 1 (1.6%) |
| Non-cancer (%) | 21 (100%) | 62 (98.4%) |

*a t-test found no significant difference in mean ages between the groups; *p* > .05  
*b* X²-test found no significant difference in gender between groups; *p* > .05  
*c* Fisher’s exact test found no significant difference in diagnosis between groups; *p* > .05

### Table 3 PaPaS scores at Second Assessment (N = 84)

| PaPaS scores (with suggested action) | Continued service (n = 63) | Discharged (n = 21) |
|-------------------------------------|---------------------------|---------------------|
| 0–14 (Not for PPC) | | |
| Number of patients (% of column) | 11 (17.46%) | 21 (100%) |
| 15 and above (For PPC) | | |
| Number of patients (% of column) | 52 (82.54%) | 0 |
| Mean score *a* (SD) | 19.25 (4.74) | 7.86 (2.39) |

*a* Difference of mean scores between groups = 11.39 (95% CI: 9.86–12.93); *t*-test: *p* < .001
Table 4 Domain-specific observations and comments for PaPaS for assessment of patients

| Domain Item                                                                 | Characteristics                                                                 | Score | Comments & Recommendations (If any)                                                                 |
|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------|
| **1.1 Trajectory of disease and impact on daily activities of the child**   | Stable                                                                           | (0)   | 1. Though the two measured constructs (disease trajectory and impact on daily activities) are    |
|                                                                            | Slowly deteriorating without impact on daily activities                         | (1)   | related, they can vary independently. Both should be scored separately.                          |
|                                                                            | Unstable; with impact on and restriction of daily activities                   | (2)   | 2. Children with life-limiting conditions generally have longer disease trajectories. It is      |
|                                                                            | Significant deterioration with severe restriction of daily activities         | (4)   | recommended that the reference baseline for Activities of Daily Living be extended to 3 months    |
|                                                                            |                                                                                  |       | (instead of just 4 weeks) to maximise detection of change.                                       |
| **1.2 Increase of hospital admissions, (> 50% within 3 months, compared to** | No                                                                               | (0)   | 1. As hospital admissions are used here as a proxy for disease severity and worsening trajectory, |
|     previous periods)                                                       | Yes                                                                              | (3)   | the purpose and type of hospital stay should be considered. Elective admissions should not be    |
|                                                                            |                                                                                  |       | included, as they could be for routine work-up (e.g. sleep studies).                              |
|                                                                            |                                                                                  |       | 2. Instead of 3 months, admissions over the last 6 months is suggested to better capture medical   |
|                                                                            |                                                                                  |       | instability for patients with predominantly longer prognoses and variable trajectories in PPC.    |
| **2.1 Treatment directed at the disease, (does not mean treatment of**      | … is curative                                                                    | (0)   | 1. To assess disease acuity based on potential treatment options, it may be helpful to qualify   |
|     disease related complications, such as pain, dyspnoea or fatigue)      | … controls disease and prolongs life with good quality of life                  | (1)   | with an additional statement like “treatments directed at the disease, even if not administered”, |
|                                                                            | … does not cure or control but has a positive effect on quality of life         | (2)   | as it was observed that many patients might not have received treatments, either due to          |
|                                                                            | … does not control and has no effect on quality of life                         | (4)   | unavailability, or they were declined by caregivers.                                            |
| **2.2 Burden of treatment, (Burden means side effects of treatment and**    | No or minimal burden or no treatment is envisioned                              | (0)   | 1. It may be helpful to qualify further “Burden of treatments, both disease-directed and         |
|     additional burdens such as stay in hospital in the patient’s or family’s| Low level of burden                                                            | (1)   | symptom-directed”. Treatments that are not directed at the underlying disease should also be      |
|     view)                                                                   | Medium level of burden                                                          | (2)   | included for consideration, as they do exact a toll on the patient and caregiver (e.g. newly      |
|                                                                            | High level of burden                                                            | (4)   | ventilator-dependent) [28–32]. 2. Burden is often contingent on the intensity and caregiver       |
|                                                                            |                                                                                  |       | skills required to administer treatment. Points of reference should be provided to ensure        |
|                                                                            |                                                                                  |       | agreement between assessors for each level of burden (e.g. invasive treatments should be scored   |
|                                                                            |                                                                                  |       | as high level of burden).                                                                        |
| **3.1 Symptom intensity or difficulty of symptom control (over the last**    | Patient is asymptomatic                                                         | (0)   | 1. Similar to Item 1.1, the two measured constructs (severity of symptoms and difficulty in       |
|     4 weeks)                                                                | Symptom(s) are mild and easy to control                                          | (1)   | management) should be scored separately, to account for differential variations.                  |
|                                                                            | Any symptom is moderate and controllable                                        | (2)   | 2. The reference baseline should be extended to “within the past 3 months”, to maximise detection |
|                                                                            | Any symptom is severe or difficult to control (unplanned hospitalisation or     | (4)   | of symptom related issues.                                                                      |
|     outpatient visits, symptom crises)                                      |                                                                                  |       |                                                                                                  |
| **3.2 Psychological distress of patient related to symptoms**              | Absent                                                                          | (0)   | 1. While psychological distress is inherent in complex care [33, 34], it may be challenging to   |
|                                                                            | Mild                                                                             | (1)   | assess this accurately as these young children may struggle to articulate distress, are non-      |
|                                                                            | Moderate                                                                        | (2)   | communicative, or cognitively impaired [33]. A proxy report – via either caregivers or the health- |
|                                                                            | Significant                                                                     | (4)   | care professional – is often required. If appropriate, this can be explicitly specified.          |
| **3.3 Psychological distress of parents or family related to symptoms and** | Absent                                                                          | (0)   | 1. To be accurately evaluated, psychological distress may require professional assessment. It     |
|     suffering of the child                                                  | Mild                                                                             | (1)   | may be difficult for most clinicians to score distress in caregivers objectively or ensure        |
|                                                                            | Moderate                                                                        | (2)   | consistency between observers in that case.                                                      |
|                                                                            | Significant                                                                     | (4)   |                                                                                                  |
There are a number of factors that limit this study's conclusions. First, we did not track patients who were rejected for admission or were deemed by primary physicians not to require PPC. Hence, the ability of the PaPaS to identify patients unsuitable for admission to PPC cannot be commented. Moreover, the study involves a retrospective review of clinical data, which did not always map specifically to items in the PaPaS. Further research can employ prospective designs where the PaPaS is used directly to assess new referrals. Second, 18 of included patients in this study were below one year of age, which was excluded in the original conceptualisation of PaPaS due to perceived differences in needs [22]. Patients beyond 19 years of age were also included in the study. As the goal was to evaluate the utility of the PaPaS in identifying eligible patients for home-based PPC as established, we had included all admitted patients, regardless of age. Third, this study did not examine inter-rater reliability. Hence, potential variability in scoring between users cannot be commented. These differences may apply to attributes that are inherently not easily quantifiable, such as psychological distress. We identified this potential issue and suggested the incorporation of cues. Still, the reliability attributes of this tool should be evaluated in future reviews. The modified scale proposed here is intended to mirror the score ranges of the original instrument as much as possible. Psychometric testing of the revised scale however, is beyond the scope of this study.

Our study findings may not be generalisable to other settings outside of home-based PPC, for example, in an in-patient palliative consult service. Similarly, perceptions of monetary concerns or other related burdens can vary in contexts with different healthcare financing systems, culture, and values. Lastly, the end-user experience should also be examined in future studies, to ensure that the PaPaS does not create additional barriers for referrals to PPC.

**Conclusion**

While there are limitations in the PaPaS as an assessment tool for identifying patients with PPC needs, it demonstrates clear benefits for adoption within individual services and potentially the healthcare system. When deployed within a home hospice setting, the PaPaS has demonstrated positive qualities in terms of objectivity, transparency and accountability.

There is a tendency to over/under-estimate the need or even intensity of care, across different professionals and care settings. The PaPaS promotes greater clarity and effective handover for everyone involved, particularly at care transitions. This can lead to important outcomes like alignment of expectations.

---

**Table 4** Domain-specific observations and comments for PaPaS for assessment of patients (Continued)

| Domain Item | Characteristics | Score | Comments & Recommendations (If any) |
|-------------|-----------------|-------|-------------------------------------|
| 5.1 Estimated life expectancy | Several years | (0) | 1. There is ambiguity to the terms ‘weeks’ and ‘months’ as it is in the original scale. For example, it is unclear whether children with a prognosis of three to four weeks should be scored 3 or 4. Life expectancies can be better clarified using defined cut-offs, e.g. ‘3 months to 1 year’, ‘3 weeks to 3 months’, ‘less than 3 weeks’. |
| | Months to 1–2 years | (1) | |
| | Weeks to months Please skip 5.2 | (3) | |
| | Days to weeks Please skip 5.2 | (4) | |
| 5.2 “Would you be surprised if this child were to suddenly die in 6 months’ time?” | Yes | (0) | 1. The word ‘suddenly’ presents difficulty as it may be challenging to determine what changes in trajectories are considered sudden. It may exclude patients who die after slow deterioration, even within 6 months, if literally interpreted. Removing the term ensures that all patients who are at-risk of dying within 6 months are accounted for during scoring. |
| | No | (2) | |
between stakeholders, and critically, optimal case management.

Ultimately, the child and family living with life-shortening illness is flagged in a timely manner to receive palliative care based on needs rather than prognosis, in spite of challenges posed by disease diversity and uncertain trajectories, through a process of screening that is both robust and informational, yet with cost-containing implications.

**Appendix**

**Proposed revision for the Pediatric Palliative Screening scale (PaPaS) and cut-off scores**

| Domain | Item | Characteristic | Score |
|--------|------|----------------|-------|
| Domain 1 | Trajectory of disease and impact on daily activities of the child |  | |
| 1.1.1 | With reference to the past 3 months, the disease trajectory of the child, in comparison with the child's own baseline, is... | ...Stable | 0 |
| | | ...Stable, but slowly deteriorating | 1 |
| | | ...Unstable with slow deterioration | 2 |
| | | ...Unstable with significant deterioration | 4 |
| 1.1.2 | With reference to the past 3 months, the impact of condition on daily activities of the child, in comparison with the child's own baseline. | No impact | 0 |
| | | Daily activities are impacted/restricted | 1 |
| | | Daily activities are severely impacted/restricted | 2 |
| 1.2 | In the past 6 months, there was a more than 50% increase in unplanned hospital admissions (compared to previous periods) | No | 0 |
| | | Yes | 3 |
| Domain 2 | Expected outcome of treatment directed at the disease and burden of treatment |  | |
| 2.1 | Treatment directed at the disease, even if not administered... (does not include treatment of disease-related complications, such as pain, dyspnea or fatigue) | ...is curative. | 0 |
| | | ...controls disease and prolongs life with good quality of life. | 1 |
| | | ...does not cure or control but has a positive effect on quality of life. | 2 |
| | | ...does not control and has no effect on quality of life. | 4 |
| 2.2 | Burden of treatment, including both disease-directed and symptom-directed treatments (consider frequency and skills involved; e.g. side effects, hospital stay, additional tasks for patients/ caregivers) | No/minimal burden OR no treatment is planned | 0 |
| | | Low level of burden (e.g., simple oral medication or diet modification) | 1 |
| | | Medium level of burden (e.g., feeding tubes, catheters, medications with adverse effects) | 2 |

**Appendix (Continued)**

| Domain | Item | Characteristic | Score |
|--------|------|----------------|-------|
| 3 | Symptom and problem burden | Patient is asymptomatic | 0 |
| | | (Please skip 3.1.2) | |
| | | Symptom(s) are mild | 1 |
| | | Symptom(s) are moderate | 2 |
| | | Symptom(s) are severe | 4 |
| | | (Please skip 3.1.2) | |
| | | Symptom(s) are easy to control | 0 |
| | | Symptom(s) are controllable | 1 |
| | | Symptom(s) are difficult to control | 2 |
| 3.1.1 | Symptom intensity over the past 3 months (consider unplanned hospitalization or outpatient visits, symptom crises) | Absent | 0 |
| | | Mild | 1 |
| | | Moderate | 2 |
| | | Significant | 4 |
| | | (Please skip 3.1.2) | |
| | | Symptom(s) are asymptomatic | 0 |
| | | Symptom(s) are mild | 1 |
| | | Symptom(s) are moderate | 2 |
| | | Symptom(s) are severe | 4 |
| | | (Please skip 3.1.2) | |
| | | Symptom(s) are easy to control | 0 |
| | | Symptom(s) are controllable | 1 |
| | | Symptom(s) are difficult to control | 2 |
| 3.2 | Psychological distress of patient related to symptoms | Absent | 0 |
| | | Mild | 1 |
| | | Moderate | 2 |
| | | Significant | 4 |
| 3.3 | Psychological distress of parents or family related to symptoms and suffering of the child | Absent | 0 |
| | | Mild | 1 |
| | | Moderate | 2 |
| | | Significant | 4 |
| Domain 4 | Preferences/needs of patient or parents and Preferences of health professional | No | 0 |
| | | Yes (Please skip 4.2) | 4 |
| 4.1 | Patient/parents wish to receive palliative care or formulate needs that are best met by palliative care. | No | 0 |
| | | Yes (Please skip 4.2) | 4 |
| 4.2 | You/your team feel that this patient would benefit from palliative care. | No | 0 |
| | | Yes | 4 |
| Domain 5 | Estimated life expectancy | Several years | 0 |
| | | 1–2 years | 1 |
| | | 3 months to a year (Please skip 5.2) | 3 |
| | | Less than 3 months (Please skip 5.2) | 4 |
| 5.1 | Estimated life expectancy/ Prognosis | Yes | 0 |
| | | No | 2 |
| 5.2 | Would you be surprised if this child died in 6 months’ time? | Yes | 0 |
| | | No | 2 |

**Total Score**
**Abbreviations**

MDT: Multi-Disciplinary Team; PaPaS: Paediatric Palliative Screening Scale; PPC: Paediatric Palliative care

**Acknowledgments**

Not applicable.

**Authors’ contributions**

JS analyzed and interpreted clinical data to impute the patients’ PaPaS scores; PHC provided internal validation. PHC, ZZY, RQA and CT were major contributors in writing the manuscript. All authors have read and approved the manuscript.

**Funding**

The authors declare that this study was not funded.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Ethics review was not sought from an Institutional Review Board. This study was a non-interventional, retrospective study using data that was collected as part of service provision. No information was directly collected from human participants for the conduct of this study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. HCA Hospice Care, 705 Serangoon Road, #03-01 Block A @ Kwong Wai Shiu Hospital, Singapore 328127, Singapore. 2. Ministry of Health Holdings, Singapore, Singapore.

**Received:** 19 July 2019 **Accepted:** 6 February 2020

**Published online:** 10 February 2020

**References**

1. Jünger S, Pastrana T, Pletzinger M, Kern M, Zemikow B, Radbruch L. Barriers and needs in paediatric palliative home care in Germany: a qualitative interview study with professional experts. BMC Palliat Care. 2010;9(1):10.

2. Williams-Reade J, Lamson AL, Knight SM, White MB, Ballard SM, Desai PP. Paediatric palliative care: a review of needs, obstacles and the future. J Nurs Manag. 2015;23(1):4-14.

3. Chong PH, Hamshah E, Goh C. Paediatric palliative care in the Asia Pacific region: where are we now? BMJ Support Palliat Care. 2017;7(1):17–22.

4. Knapp C, Woodworth L, Wright M, Downing J, Drake R, Fowler-Kenney S, et al. Pediatric palliative care provision around the world: a systematic review. Pediatr Blood Cancer. 2011;57(3):361–8.

5. Worldwide Palliative Care Alliance. Global atlas of palliative care at the end of life: World Health Organization Website: Worldwide Palliative Care Alliance; 2014. Available from: https://www.who.int/nmh/GlobalAtlas_of_Palliative_Care.pdf. Accessed 22 Apr 2019.

6. Ventura AD, Burney S, Brooker J, Fletcher J, Ricciardielli L. Home-based palliative care: a systematic literature review of the self-reported unmet needs of patients and carers. Palliat Med. 2014;28(5):391–402.

7. Miller AR, Condin CJ, McKellin WH, Shaw N, Klassen AF, Sheps S. Continuity of care for children with complex chronic health conditions: parents’ perspectives. BMC Health Serv Res. 2009;9(1):242.

8. Spalthis A, Harrop E, Robertshaw C, Elvenson J, Lapwood S. Learning from paediatric palliative care: lessons for adult practice. Palliat Med. 2012;26(6):777–9.

9. Wood F, Simpson S, Barnes E, Hain R. Disease trajectories and ACT/RCPC categories in paediatric palliative care. Palliat Med. 2010;24(8):796–806.

10. Fraser LK, Lidstone V, Miller M, Aldridge J, Norman P, McKinney PA, et al. Patterns of diagnoses among children and young adults with life-limiting conditions: a secondary analysis of a national dataset. Palliat Med. 2014;28(6):513–20.

11. Lindley LC, Lyon ME. A profile of children with complex chronic conditions at end of life among Medicaid beneficiaries: implications for health care reform. J Palliat Med. 2013;16(11):1388–93.

12. Feudtner C, Kang TI, Hexem KR, Friedrichsdorf SJ, Osenga K, Siden H, et al. Pediatric palliative care patients: a prospective multicenter cohort study. Pediatrics. 2011;127(6):1094–101.

13. Liston V. The role of hospices in supporting young people in transition from children to adult services. London: Help the Hospices Commission; 2013.

14. Taylor LK, Miller M, Joffe T, Parslow RC, Aldridge J, Bailey CC, et al. Palliative care in Yorkshire, UK 1987–2008: survival and mortality in a hospice. Arch Dis Child. 2010;95(2):89–93.

15. Inglin S, Hornung R, Bergstraesser E. Palliative care for children and adolescents in Switzerland: a needs analysis across three diagnostic groups. Eur J Pediatr. 2011;170(8):1031–8.

16. Brook LA, Kerr C, Hawker S. Defining children who may have palliative care needs: a delphi consensus building study. Arch Dis Child. 2011;96(Suppl 1):A79.

17. European Association for Palliative Care. IMPaCCT: standards for paediatric palliative care. Eur J Pediatr. 2009;168(14):1782–7.

18. Freibert S, Osenga K. Pediatric palliative care referral criteria. In: Pediatric palliative care referral criteria. Center to Advance Palliative Care. 2009. 22. Bergstraesser E, Paul M, Rufibach K, Hain RD, Pereira JL. The development of an instrument that can identify children with palliative care needs: a classification framework for children with life-limiting or life-threatening conditions. BMJ Support Palliat Care. 2015;5(3):249–58.

19. Harrop E, Edwards C. How and when to refer a child for specialist paediatric palliative care. Arch Dis Child Educ Pract Ed. 2013;98(6):202.

20. Burke K, Coombes LH, Menezes A, Anderson AK. The ‘surprise’ question in paediatric palliative care: a prospective cohort study. Palliat Med. 2018;32(2):535–42.

21. Shaw KL, Brook L, Mpundu-Kaambwa C, Harris N, Lapwood S, Randall D. The Spectrum of children’s palliative care needs: a classification framework for children with life-limiting or life-threatening conditions. BMJ Support Palliat Care. 2015;5(3):249–58.

22. Bergstraesser E, Hain RD, Pereira JL. The development of an instrument that can identify children with palliative care needs: the Paediatric palliative screening scale (PaPaS scale): a qualitative study approach. BMC Palliat Care. 2013;12(1):20.

23. Bergstraesser E, Paul M, Rufibach K, Hain RD, Held L. The Paediatric palliative screening scale: further validation testing. Palliat Med. 2014;28(6):530–3.

24. Bosuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2013: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.

25. Thompson LA, Knapp C, Madden V, Shenkmann E. Pediatricians’ perceptions of and preferred timing for pediatric palliative care. Pediatrics. 2009;123(5):e777–e82.

26. Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting: a consensus report from the center to advance palliative care. J Palliat Med. 2010;14(17):13–23.

27. Chong PH, De Castro Molina JA, Teo K, Tan WS. Paediatric palliative care improves patient outcomes and reduces healthcare costs: evaluation of a home-based program. BMC Palliat Care. 2018;17(1):11.

28. de Souza EJ, da Silva LF, Santos da Conceicao D, Dorea Paiva E. Families of children with complex chronic conditions: parents’ perspectives. BMC Health Serv Res. 2009;9(1):242.

29. Feudtner C, Kang TI, Hexem KR, Friedrichsdorf SJ, Osenga K, Siden H, et al. Continuity of care for children with complex chronic health conditions: parents’ perspectives. BMC Health Serv Res. 2009;9(1):242.

30. Moskowitz JT, Butensky E, Harmatz P, Vichinsky E, Heyman MB, Acree M, et al. Caregiving time in sickle cell disease: psychological effects in maternal caregivers. Pediatr Blood Cancer. 2007;48(1):64–71.

31. Raina P, O’Donnell M, Rosenbaum P, Breihaut J, Walter SD, Russell D, et al. The health and well-being of caregivers of children with cerebral palsy. Pediatrics. 2005;115(6):e626–36.
32. Toly VB, Musil CM, Carl JC. Families with children who are technology dependent: normalization and family functioning. West J Nurs Res. 2012; 34(1):52–71.
33. Cadman D, Rosenbaum P, Boyle M, Offord DR. Children with chronic illness: family and parent demographic characteristics and psychosocial adjustment. Pediatrics. 1991;87(6):884.
34. Perrin JM, Gnanasekaran S, Delahaye J. Psychological aspects of chronic health conditions. Pediatr Rev. 2012;33(3):99–109.
35. Chong PH. What do physicians think about paediatric palliative care? A survey in Singapore. Eur Jour Pall Car. 2014;21(2):93–7.
36. Twamley K, Craig F, Kelly P, Hollowell DR, Mendoza P, Bluebond-Langner M. Underlying barriers to referral to paediatric palliative care services: knowledge and attitudes of health care professionals in a paediatric tertiary care Centre in the United Kingdom. J Child Health Care. 2013;18(1):19–30.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.